MUMBAI, July 2 (Reuters) - India's Sun Pharmaceutical Industries (SUN.BO) said on Thursday it had got tentative approval from the U.S. Food and Drug Administration for marketing the generic version of Optivar.
The drug is used for treatment of eye itching connected to conjunctivitis. (Reporting by Narayanan Somasundaram)
© Thomson Reuters 2009 All rights reserved
Mini-dress drama in brazil
Obama vows "justice" for shooter
Boston woman's near miss on subway
Hero medal for Kalashnikov's 90th
Deadly car bomb in Pakistan
Car bomb explodes in Pakistani town
Sen. Dodd unveils reform plan
Strong winds for China power IPO
APEC eyed for global boost
DC sniper to be executed
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
